Cite
Anhydroicaritin, a SREBPs inhibitor, inhibits RANKL-induced osteoclastic differentiation and improves diabetic osteoporosis in STZ-induced mice.
MLA
Zheng, Zu-Guo, et al. “Anhydroicaritin, a SREBPs Inhibitor, Inhibits RANKL-Induced Osteoclastic Differentiation and Improves Diabetic Osteoporosis in STZ-Induced Mice.” European Journal of Pharmacology, vol. 809, Aug. 2017, pp. 156–62. EBSCOhost, https://doi.org/10.1016/j.ejphar.2017.05.017.
APA
Zheng, Z.-G., Zhang, X., Zhou, Y.-P., Lu, C., Thu, P. M., Qian, C., Zhang, M., Li, P., Li, H.-J., & Xu, X. (2017). Anhydroicaritin, a SREBPs inhibitor, inhibits RANKL-induced osteoclastic differentiation and improves diabetic osteoporosis in STZ-induced mice. European Journal of Pharmacology, 809, 156–162. https://doi.org/10.1016/j.ejphar.2017.05.017
Chicago
Zheng, Zu-Guo, Xin Zhang, Ya-Ping Zhou, Chong Lu, Pyone Myat Thu, Cheng Qian, Mu Zhang, Ping Li, Hui-Jun Li, and Xiaojun Xu. 2017. “Anhydroicaritin, a SREBPs Inhibitor, Inhibits RANKL-Induced Osteoclastic Differentiation and Improves Diabetic Osteoporosis in STZ-Induced Mice.” European Journal of Pharmacology 809 (August): 156–62. doi:10.1016/j.ejphar.2017.05.017.